


Cooperating to Control COVID-19

ACT-Accelerator at 18 months

DCVMN ANNUAL GENERAL MEETING

19 OCTOBER 2021

ACT now. ACT together to accelerate the end of the COVID-19 crisis



COVID-19 has a devastating impact on the world

~250
million

Reported cases

Oct 2021

~5
million

Reported deaths

Oct 2021

>9
trillion

US\$ loss in global output

IMF; October 2020

ACT-A was created to save lives & the economy



Working with Governments, industry, CSO & development system for impact

ACT-Accelerator's core focus:

- accelerate development of tests, treatments & vaccines
- ensure equitable access globally

In its 1st year, ACT-Accelerator fundamentally improved our ability to tackle COVID-19 globally



Vaccines: can prevent COVID-19 everywhere



Tests: can now quickly detect COVID anywhere



Treatments: can save lives anywhere (e.g O₂ & steroids)



Equitable Access: for uptake & use everywhere



Health systems support to deliver new products & PPE
Global Access & Allocation mechanisms

But equitable access has not kept pace with the development of COVID-19 tools

Why India's Covid crisis matters to the whole world

By Rebecca Morelle
Global science correspondent, BBC News

5 days ago

Coronavirus pandemic



The harrowing scenes from India have shocked the world, as it struggles with soaring cases of Covid.

But the outbreak isn't just a crisis for India - it's a crisis for ever

India's Covid-19 Tragedy Is Now The World's Problem



William Pesek Senior Contributor

Asia

I write about economics, markets and policymaking throughout



Covid in Brazil: Hunger worsens in city slums

By Mack Lowen
BBC News, São Paulo

18 April

Coronavirus pandemic



The crisis caused by the pandemic has forced a growing number of people to depend on food donations

The queue snakes around the block and each day it gets longer: hungry residents of Heliópolis, São Paulo's largest favela, waiting in line for the handout that will keep them going until the next morning.

7 Oct...a new call to action COVID-19 vaccines



World Health Organization

Strategy to Achieve Global Covid-19 Vaccination by mid-2022

Strategy to Achieve Global Covid-19 Vaccination by mid-2022

Given ongoing vaccine supply constraints, for greatest impact and equity it is critical to vaccinate in a stepwise, internationally coordinated manner with time-bound coverage targets:

- * by end September 2021 10% coverage in all countries
- * by end December 2021 40% coverage in all countries
- * by end June 2022 70% coverage in all countries

The 70% coverage target by mid-2022 is driven by the health and economic imperatives of stopping the pandemic as rapidly as possible, supported by technical analyses on disease epidemiology and vaccine attributes, and a feasibility assessment that includes requirements on global vaccine production and national absorption capacities.¹ The interim coverage targets are needed to ensure an equitable pace of vaccine rollout globally and appropriate prioritisation of vaccine for those at highest risk. The 10% coverage target by end September 2021 was met over by 56 countries, representing 20% of the global population. As of the end of September, 70 countries had already met the 40% coverage target. This makes ever more urgent the critical actions needed to ensure that the remaining countries, and especially those that are still below 10% coverage, are on a trajectory to achieve the 40% coverage by end December 2021.

The promise of COVID-19 vaccines in ending the pandemic can only be realized if all countries act together with urgency, optimizing the strategic use of the limited but growing vaccine supply.

Figure 2. COVID-19 full vaccination population coverage targets for 2021 - 2022




¹ National targets may need to be adjusted based on age demographics, policy developments and programme needs.
² The 70% coverage target by mid-2022 is also consistent with the downside risk scenario envisioned in the original RFI proposal released in July 2021 and endorsed by the Multilateral Leaders' Declaration (MLD).

A role for everyone

Figure 3. Aligned and coordinated action to achieve the global COVID-19 vaccination targets

- | All Countries | High Coverage Countries | CSOs, Private Sector | WHA, Gavi, UNICEF, COV | MDGs and Institutions | Manufacturers |
|--|--|---|---|---|--|
| Finalize national plans and commit to equitable vaccine distribution, including free flow of materials and vaccines; thoroughly report local data through aJRP | Take urgent actions to get vaccine doses to lower coverage countries through COVAX, AWAT and other means | Engage people, communities and partners locally and globally to act in support of demand and equity | Ensure COVAX's success and support end-to-end impact for equitable, high coverage | Continue to ensure sufficient funding and support for procurement | Ensure supply and transparency to ensure global equity and share knowledge |




Transparency and data as critical enablers, including from manufacturers on 'place in the queue' and bilateral deals, and from countries on accurate and complete data reporting

Ambitious targets


ACT-Accelerator: the next 12 months

The COVID-19 crisis is not over | despite a perceived return to 'normality', transmission & mortality remain high


New waves continue to spread around the globe...




...& mortality remains high



Oct '20
~5,800 daily new deaths




April '21
~10,900 daily new deaths



Oct '21
~7,700 daily new deaths

And with an evolving virus ACT-A's longterm, integrated approach is essential

New variants challenge herd immunity...



...making full package essential



High **vaccine** coverage to reduce disease & deaths



Testing to guide response & save lives




Lifesaving **O₂** & **treatments**



PPE to reduce exposure


&



Public health & social measures

Escalating inequity is resulting in a 2-track pandemic

Vaccine inequities




If this inequity continues...

>5m
lives lost in
2022 alone

Testing inequities

(daily tests / 100K pop) at end-Sept





\$5.3tr
economic cost
by 2026

ACT-A is crucial to solving inequity

COVAX already delivers 80% of LIC vaccines

ACT-A Dx delivers >80% of tests for >20 LICs



ACT-A has crucial contribution to global COVID-19 targets over the next 12 months

ACT-A CONTRIBUTION TO GLOBAL TARGETS




Vaccines

Support countries' vaccination goals towards...

70%

coverage in AMC91 countries




Diagnostics

Advance testing rates to a minimum of...

100 | **100K**
tests | pop/day

in Dx144 countries



Treatments (incl. O2)

Aim to treat up to...

120 Mn

cases in LICs, LMICs, key UMICs



PPE

Provide high quality PPE to protect over...

2.7 Mn



HCWs in LICs, LMICs, key UMICs

Next week.....

ACT-Accelerator Strategic Plan & Budget, Oct 2021-Sep 2022

Ambitious equity targets

A \$22 Bn budget



...in run up to the G20 Summit

Summary

If inequitable access to COVID-19 tools continues...

- **5M lives** could be lost in 2022
- **US\$ 5.3 Tr in lost revenues** by 2026

ACT-A has a crucial role in solving this inequity,
esp. to close gaps to minimum global targets

Monthly economic losses = 4x entire ACT-A budget

DCVMN is a crucial & central part of ACT-A & is
even more vital to rapidly solve inequity